Chuck Murry, MD, PhD, a physician-scientist and pioneer in heart regeneration. Dr. Murry is the Director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, and the Chair of the Department of Stem Cell Biology and Regenerative Medicine. Prior to joining USC, Murry was a Professor of Laboratory Medicine & Pathology, Bioengineering and Medicine/Cardiology and the Director of the Institute for Stem Cell and Regenerative Medicine (ISCRM) at the University of Washington. Previously Dr. Murry served as Senior Vice-President at Sana Biotechnology to establish clinical-grade induced pluripotent stem cell (iPSC) based cardiac cell manufacturing.

Lil Pabon, PhD is a developmental biologist by training with 20+ years of experience with human pluripotent stem cells and their application towards cardiovascular regenerative medicine. As a Senior Scientist and Research Operations Director she helped establish the scientific foundation for the Heart Regeneration Program at the University of Washington (UW). At Sana Biotechnology, Dr. Pabon served as Head of Research Operations, Cell Therapy until co-founding StemCardia to develop next generation cell-based cardiac therapies targeting heart disease.

Carter Cliff is a pioneering serial entrepreneur with a proven track record of translating breakthrough science into clinical-stage cell therapies. He has co-founded or led eleven ventures that have collectively raised over $270 million. Highlighted transactions include Opsis Therapeutics’ strategic R&D alliance with Bayer, including a $70 million up-front, and Kenai Therapeutics’ $82 million Series A financing. He is committed to advancing disease-modifying and potentially curative new medicines for serious inherited and age-related conditions.

Robb MacLellan, MD, serves as the Robert A. Bruce Professor of Medicine and Executive Vice-Chair of the Department of Medicine at University o of Washington (UW), where he led the Cardiology Division at UW from 2011-23, and as the Director of the UW Medicine Heart Institute, a multi-disciplinary service line with four hospitals and 4 additional satellite clinics. His clinical expertise is in heart failure, and is a prominent investigator in cardiovascular regenerative medicine with research focused on developing new therapies to regenerate the heart for patients who have suffered a heart attack or developed heart failure.

Michael Regnier, PhD, is a scientific advisor to StemCardia. He is the Associate Chair for Research and Development in the Department of Bioengineering at University of Washington (UW) and the founding director of the Center for Translational Muscle Research and Bioengineering Cardiovascular Training Program. His research program is multidisciplinary in nature and has been consistently funded by the National Institutes of Health and other public and private agencies for over 25 years to study contractile dysfunction that occurs with heart and skeletal muscle diseases. The results of studies are used to design and develop gene and engineered stem cell approaches to treat these muscle diseases.